O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.46 CNY 1.11% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Obio Technology Shanghai Corp Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Operating Income
-ÂĄ170.6m
CAGR 3-Years
N/A
CAGR 5-Years
-39%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Operating Income
ÂĄ10.6B
CAGR 3-Years
33%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Operating Income
ÂĄ1.6B
CAGR 3-Years
5%
CAGR 5-Years
23%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Operating Income
ÂĄ3.9B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Operating Income
ÂĄ1.4B
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
27%
W
WuXi XDC Cayman Inc
HKEX:2268
Operating Income
ÂĄ410.8m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.56 CNY
Overvaluation 17%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Operating Income?
Operating Income
-170.6m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Operating Income amounts to -170.6m CNY.

What is Obio Technology Shanghai Corp Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-39%

Back to Top